Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- COEPW
- Price
- 0.01
- Stock movement down
- -0.00 (-6.38%)
- Company name
- Coeptis Therapeutics Holdings Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- 2.84M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -77.32%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
COEPW does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | 0.94 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -0.29 |
| FCF per share (TTM) | -0.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.00M |
| Gross profit (TTM) | 319.82K |
| Operating income (TTM) | -11.26M |
| Net income (TTM) | -11.62M |
| EPS (TTM) | -0.29 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 10.65% |
| Operating margin (TTM) | -374.81% |
| Profit margin (TTM) | -386.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.14M |
| Net receivables | 0.00 |
| Total current assets | 1.36M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 94.79K |
| Total assets | 8.96M |
| Accounts payable | 1.13M |
| Short/Current long term debt | 1.77M |
| Total current liabilities | 3.44M |
| Total liabilities | 3.97M |
| Shareholder's equity | 4.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -6.91M |
| Capital expenditures (TTM) | 1.00 |
| Free cash flow (TTM) | -6.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -233.24% |
| Return on Assets | -129.76% |
| Return on Invested Capital | -173.55% |
| Cash Return on Invested Capital | -103.14% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.01 |
| Daily high | 0.01 |
| Daily low | 0.01 |
| Daily Volume | 6K |
| All-time high | 0.19 |
| 1y analyst estimate | - |
| Beta | -0.59 |
| EPS (TTM) | -0.29 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| COEPW | S&P500 | |
| Current price drop from All-time high | -95.48% | -17.56% |
| Highest price drop | -95.89% | -56.47% |
| Date of highest drop | 1 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -65.81% | -11.07% |
| Avg time to new high | 21 days | 12 days |
| Max time to new high | 419 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner